Overview

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

Status:
Terminated
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with diffuse cutaneous systemic sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Corbus Pharmaceuticals Inc.